WB, IP
H
Endogenous
100
Rabbit
#Q86UT6
79671
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Species predicted to react based on 100% sequence homology
The antigen sequence used to produce this antibody shares
100% sequence homology with the species listed here, but
reactivity has not been tested or confirmed to work by CST.
Use of this product with these species is not covered under
our
Product Performance Guarantee.
Monkey
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys441 of human NLRX1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
The nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family of proteins is a diverse family of cytoplasmic innate immune receptors. They are characterized by the presence of an amino-terminal effector domain, which is often either a caspase activation and recruitment domain (CARD) or a pyrin domain (PYD), followed by a NACHT domain and carboxy-terminal leucine-rich-repeats (LRR) involved in recognition of pathogen-associated molecular patterns (PAMPs) (1). NLR proteins play a variety of roles during the innate immune response including pathogen sensing, transcriptional activation of proinflammatory cytokines through NF-κB, transcriptional activation of type I interferons through IRFs, and formation of inflammasomes leading to activation of inflammatory caspases (1-7).
NLRX1 (CLR11.3/NOD26/NOD5/NOD9) is unique among NLR family members in that it contains an amino-terminal mitochondrial targeting sequence resulting in localization to the mitochondria (8,9). In contrast to most NLR proteins, NLRX1 has been shown to act as a negative regulator of innate immune responses through inhibition of MAVS-Rig-I signaling, as well as inhibition of Toll-like receptor (TLR)-mediated NF-κB activation (9-11). In addition, overexpression of NLRX1 enhanced the production of reactive oxygen species (ROS), resulting in prolonged NF-κB and JNK signaling in response to TNF-α (8).
- Elinav, E. et al. (2011) Immunity 34, 665-79.
- Inohara, N. et al. (1999) J Biol Chem 274, 14560-7.
- Ogura, Y. et al. (2001) J Biol Chem 276, 4812-8.
- Sabbah, A. et al. (2009) Nat Immunol 10, 1073-80.
- Mariathasan, S. et al. (2004) Nature 430, 213-8.
- Agostini, L. et al. (2004) Immunity 20, 319-25.
- Martinon, F. et al. (2002) Mol Cell 10, 417-26.
- Tattoli, I. et al. (2008) EMBO Rep 9, 293-300.
- Moore, C.B. et al. (2008) Nature 451, 573-7.
- Allen, I.C. et al. (2011) Immunity 34, 854-65.
- Xia, X. et al. (2011) Immunity 34, 843-53.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
